TruAlt Bioenergy Limited has submitted to the Exchange, the financial results for the period ended March 31, 2026.
TRUALT · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
TruAlt Bioenergy reported declining full-year profits for FY2026. Consolidated revenue fell to ₹1,72,751 lakhs from ₹1,90,772 lakhs in FY2025, while profit after tax dropped to ₹9,687 lakhs from ₹14,664 lakhs—a decline of about 34%. The company saw significant working capital pressure with operating cash flow turning negative at ₹(29,563) lakhs versus positive ₹34,203 lakhs in the prior year. Inventories nearly doubled to ₹52,843 lakhs while trade payables fell sharply. The company completed its IPO in October 2025 (oversubscribed 75x), raising ₹750 crore. Joint ventures with Sumitomo Corporation and GAIL were announced, and dual-feed capacity expansion was completed at three units to address seasonality.
The sharp profit decline and negative operating cash flow are concerning for shareholders. However, the company maintains an unmodified auditor opinion, and new partnerships with Sumitomo and GAIL plus the IPO-funded expansion may support future growth. The stock may face short-term pressure due to earnings decline.